Intra-Cellular Therapies ITCI announced positive top-line results from Study 502, the second late-stage study that evaluated lumateperone 42 mg for the treatment of major depressive disorder (MDD).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results